Sensydia – a non-invasive cardiac diagnostic company – announced recently that it was awarded a Fast-Track Small Business grant from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH). This award provides Sensydia with non-dilutive funding for the development and clinical testing of the machine learning algorithms for the Cardiac Performance System (CPS), which was designed to enable earlier detection and therapy guidance for patients with heart failure and pulmonary hypertension.
The Phase I of the grant proposal is budgeted for approximately $600,000 and Phase II for $2.4M, following the successful completion of Phase I milestones. And this NIH award marks a significant milestone for Sensydia, a company committed to developing AI-based solutions for the diagnosis and management of cardiopulmonary diseases. Sensydia recently raised $8M in venture funding.
The Small Business Technology Transfer (STTR) program of the NIH supports U.S.-owned small businesses through early-stage capital for creating innovative technologies to improve human health. And the STTR Fast-Track streamlines funding for Phases I and II, with feasibility established in Phase I and technology development in Phase II.
KEY QUOTES:
“We are honored to be a recipient of this competitive award from the NIH/NHLBI and look forward to unlocking the capabilities of AI-based cardiac assessment to provide personalized care to patients suffering from heart disease.”
— Aman Mahajan, MD, Sensydia Chief Medical Officer
